AlphaYou
Overview
Smart money at a glance
Filings to Oct 11, 2026Net selling: insiders sold $16K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$16K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 1 cutEven
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 11- Open
- $14.06
- 52-wk high
- $22.67
- High
- $14.86
- 52-wk low
- $11.00
- Low
- $13.94
- Prev close
- $13.99
- Mkt cap
- $1.84B
- Volume
- 903.1K
- P/S
- 69.5x
- P/B
- 4.6x
- Profit margin
- +0.0%
- Op margin
- -1134.0%
- ROE
- -81.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about GENB filings
Are insiders buying or selling Generate Biomedicines, Inc. Common Stock (GENB) stock?
Net selling: insiders sold $16K and bought $0 of GENB stock on the open market in the 90 days to Oct 11, 2026, according to SEC Form 4 filings. $16K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Arnold, Frances (Director), who sold $16K. The latest filing was on Sep 3, 2026.
Which members of Congress have traded GENB recently?
None. No member of Congress disclosed a GENB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this GENB smart-money data?
This summary uses filings available on Oct 11, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- BR
BlackRock
$28.0M
bought
- FM
FMR LLC
$52.7M
bought
Sells/Trims (1)
- JC
JPMorgan Chase
$10.1M
trimmed
What insiders are doing
Sells (1)
- AF
Arnold Frances
$16K
sold
How top traders are positioned
No tracked top-trader positions in GENB right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 8.3% below what analysts expected.
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.48 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | -$0.52 / -$0.48Alpha Vantage | -8.33% miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$1.07 / -$0.51Alpha Vantage | -109.80% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 5, 2026, in 25 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $1.8B
Valuation
- P/S69.50
- P/B4.65
Quality
- Operating margin-1134.0%
- ROE-81.7%
- ROA-34.6%
Growth
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace